Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.59 |
| ▸ | PGR | P06401 | 3/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363001 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9362738 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL3762416 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9362735 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9821457 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9821450 | 1.00 | IDO1 (0.65) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9363034 | 0.82 | CYP2C9 (0.58) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9362974 | 0.82 | ADRA2C (0.52) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9363028 | 0.82 | CYP2C9 (0.58) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| SCHEMBL9362972 | 0.82 | ADRA2C (0.52) | IDO1CYP2C9CYP3A4LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3264563-A | — | — | None | — | — | JP | disclosed |
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-0427242-B1 | Azole derivatives and antifungal drugs containing the same as an active component | KAO CORP (JP) | 1994-09-21 | — | — | EP | disclosed |
| US-5183824-A | Azole derivatives and antifungal drugs containing the same as an active component | KAO CORPORATION (JP) | 1993-02-02 | — | — | US | disclosed |
| US-5110826-A | AZOLE DERIVATIVES AND ANTIFUNGAL DRUGS CONTAINING THE SAME AS AN ACTIVE COMPONENT | KAO CORPORATION (JP) | 1992-05-05 | — | — | US | disclosed |
| JP-H03264563-A | AZOLE DERIVATIVE | KAO CORP | 1991-11-25 | — | — | JP | disclosed |
| EP-0427242-A1 | Azole derivatives and antifungal drugs containing the same as an active component | KAO CORPORATION (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | IDO1 1150/4885CYP2C9 2922/4885CYP3A4 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.